Results 71 to 80 of about 10,055 (214)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

Endometrial Stromal Sarcoma: An Update

Cancers
Endometrial stromal sarcoma (ESS) is a rare malignant tumor of uterine mesenchyme, accounting for 15–20% of uterine sarcomas. It is classified into low-grade (LG-ESS) and high-grade (HG-ESS) subtypes, each defined by distinct histopathological and molecular features.
Giulio Ricotta, Silvio Andrea Russo, Anna Fagotti, Alejandra Martinez, Elodie Gauroy, Mathilde Del, Valentin Thibaud, Bataillon Guillaume, Gwenaël Ferron   +8 more
openaire   +2 more sources

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, Volume 4, Issue 2, June 2026.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

New Insights Into the Role of Neutrophils in Lymphoma

Cancer Medicine, Volume 15, Issue 6, June 2026.
Tissue‐resident neutrophils challenge conventional paradigms by actively infiltrating normal lymphoid organs, predominantly localizing in interstitial compartments, a spatial distribution distinct from their classical vascular positioning. Neutrophils in lymphoid organs exhibit unique phenotypic and functional signatures, suggesting they play roles in ...
Ling Gu
wiley   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun, Hao Shu, Qian Zhang, Jishan Zheng, Yunyan Ma, Dengwang Chen, Jidong Zhang, Tao Song   +7 more
wiley   +1 more source

Liver metastasis of endometrial stromal sarcoma

World Journal of Hepatology, 2012
Resection of liver metastases from gynaecological tumours is uncommon. Endometrial stromal sarcomas (ESS) are low incidence gynecological tumours which can originate in previous sites of endometriosis or following metaplasia of the pelvic peritoneal wall, and which are exceptionally associated with liver metastasis.
Jose M, Ramia, Roberto, De la Plaza, Ines, Garcia, Cristian, Perna, Pilar, Veguillas, Jorge, García-Parreño   +5 more
openaire   +2 more sources

Pulmonary metastases of uterine endometrial stromal sarcoma in a young patient: An extreme rarity

Human Pathology: Case Reports, 2017
Endometrial stromal sarcoma (ESS) is a rare malignant tumor of the endometrium, usually seen in perimenopausal females. We report a case of ESS in a 24 year old woman, presenting as rapid enlargement of a uterine fibroid associated with irregular and ...
Sonia Chhabra, Namita Bhutani, Sunita Singh, Monika Sangwan, Rajeev Sen   +4 more
doaj   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

Vaccines, 2018
Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity.
Sandra Tuyaerts, Frédéric Amant
doaj   +1 more source